- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01876862
Towards HIV Functional Cure (ULTRASTOP)
A Pilot Study Evaluating the Maintenance of Viral Suppression After 24 Weeks of Therapeutic Interruption in Chronically HIV-1 Infected Patients With a Low Circulating HIV-DNA Reservoir
During the ERAMUNE-01 and -02 studies, the HIV-DNA quantification in the PBMCs (Peripheral Blood Mononuclear Cells) showed showed that some patients had a very low or undetectable reservoir.
Recent studies showed that a low reservoir is associated to a spontaneous virologic control in three specific categories of patients:
- "Elite Controllers": these rare patients are able to spontaneously maintain an HIV-RNA viral load below 50 copies/mL and elevated CD4 counts without any treatment. These patients belong to the B27/B57 haplotypes associated to a reduced risk of HIV contamination but these haplotypes are very rare in the global population (0,3 %)
- "Visconti" patients: early-treated patients, during the primo-infection stage. After 3 to 5 years of treatment, these patients are able to maintain an undetectable HIV-RNA viral load.
- "Salto" patients: these patients are treated a bit later compared to the Visconti cohort, when their CD4 count was above 350 cells/mm3 and their HIV-RNA viral load below 50 000 copies/mL. The follow-up of these patients showed the same capacity of control of the HIV infection for at least 2 years following treatment interruption.
Taking into account these 3 categories of patients which common characteristics is a low reservoir, our objective is to answer the 2 following questions:
- Is it possible to discontinue the treatment in chronically-infected patients with a "normal" immune system and with an undetectable HIV-DNA reservoir?
- Is a low viral reservoir predictive of a treatment-free remission of the HIV infection in chronically-infected patients?
The main objective of the proof-of-concept ERAMUNE-03 trial is to evaluate the proportion of patients in success (i.e. able to maintain a virologic and an immunologic control of the infection) after treatment discontinuation, failure is defined as:
- An HIV-RNA viral load > 400 copies/mL on 2 consecutive tests starting from Week 4
- Or CD4 count < 400 cells/mm3 on 2 consecutive measures starting from Week 4
- Or the onset of an AIDS-related event
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
Le Kremlin Bicêtre, France, 94275
- University hospital of Bicêtre
-
Paris, France, 75013
- Hospital Pitie-Salpetriere
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- HIV-1 infected patient
- CD4 count > 500 cells/mm3
- CD4/CD8 ratio > 0.9
- CD4 nadir > 300 cells/mm3
- HIV-1-RNA plasma viral load < 50 copies/mL under antiretroviral treatment for at least 2 years
- HIV-1-RNA plasma viral load < 20 copies/mL at baseline
- HIV-DNA reservoir < 100 copies/million PBMCs
- Signed fully informed consent form
- Ability to attend the complete schedule of assessments and patient visits
- Patient eligible for national social insurance
Exclusion Criteria:
- Medical history of AIDS-staging event
- Antiretroviral treatment initiated during primo-infection in absence of anti-HIV antibodies (negative ELISA and Western Blot tests)
- Change in the antiretroviral treatment combination within the 3 months prior inclusion
- HIV-2 co-infection
- History of thrombocytopenia (< 100 000 cells/mm3)
- Acute neurologic event during primo-infection
- Chronic and active hepatitis B as defined as positive HBs antigen or positive isolated anti-HBc antibodies
- Chronic and active hepatitis C as defined as positive anti-HCV antibodies and positive HCV-RNA PCR
- History of cancer within the 5 years prior inclusion except basocellular cutaneous cancers
- Comorbidity associated to lifespan < 12 months according investigator's opinion
- History of auto-immune disease (lupus erythematous, Hashimoto's thyroiditis, ...)
- Hemoglobin < 7 g/dL, Creatinine clearance < 60 mL/min using the MDRD formula
- Patients refusal to use a condom for any sexual relationship during the course of the study
- Refusal from women of childbearing potential to use at least one additional barrier method other than condoms
- Ongoing pregnancy as documented by a positive blood test performed at screening or later
- Lactating woman
- Psychologic unstability or patient state-of-mind incompatible with the participation in the study as evaluated by psychologist at screening
- Drug or alcohol addiction or abuse
- Concomitant participation to another trial involving any investigational treatment or device
Study Plan
How is the study designed?
Design Details
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: STOP ART
Antiretroviral treatment interruption in 3 successive groups of 5 patients. "Zero-risk" strategy If after 8 weeks of treatment interruption, at least 1 patient from group 1 does not present any of the failure criteria, patients from group 2 will be included and their treatment interrupted. If after 8 weeks of treatment interruption, at least 2 patients from groups 1 and 2 do not present any failure criteria, patients from group 3 will be included and their treatment interrupted. |
pilot study in chronically HIV-infected patients with an ultralow HIV reservoir undergoing treatment-interruption.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Proportion of patients in success
Time Frame: Week 24
|
Success is defined as the maintenance of the controlled viral infection after 24 weeks of therapeutic interruption. Failure is defined as:
|
Week 24
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Changes from baseline in CD4 and CD8 lymphocytes counts
Time Frame: Up to Week 48
|
Up to Week 48
|
|
Changes from baseline in immune activation and inflammation markers
Time Frame: Up to Week 48
|
Up to Week 48
|
|
Changes from baseline in anti-HIV specific T cells response
Time Frame: Up to Week 48
|
Up to Week 48
|
|
Quantitative and qualitative changes from baseline in the HIV-1 reservoir as measured on sorted CD4 lymphocytes subsets
Time Frame: Up to Week 48
|
CD4 subpopulations will be live-sorted and purified.
In each subset defined by surface markers, HIV-1 DNA will be quantified and transcriptional potential of HIV will be evaluated.
|
Up to Week 48
|
Proportion of patients in virologic success (HIV-1-RNA plasma viral load < 400 copies/mL)
Time Frame: Up to Week 48
|
Up to Week 48
|
|
Changes from baseline in the HIV-1 reservoir as measured by HIV-1 DNA copies per million PBMCs
Time Frame: Up to Week 48
|
Up to Week 48
|
|
Changes from baseline in the proportion of defective HIV-1 DNA
Time Frame: Up to Week 48
|
Evaluation of the stop codons in the HIV-1 DNA sequence
|
Up to Week 48
|
Changes from baseline in the plasma concentrations of antiretroviral molecules
Time Frame: Up to Week 48
|
Up to Week 48
|
|
Changes from baseline in the patient quality of life and in the disease-related symptoms
Time Frame: Up to Week 48
|
Up to Week 48
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Study Director: François LECARDONNEL, MSc, Objectif Recherche Vaccins SIDA
- Principal Investigator: Christine KATLAMA, MD, Hospital Pitie-Salpetriere
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- ORVACS 012
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Chronic HIV-1 Infection
-
Nina BhardwajNational Institute of Allergy and Infectious Diseases (NIAID); National Institutes... and other collaboratorsCompletedHIV-1 Infected Adults With Chronic HIV-1 InfectionUnited States
-
Sociedad Andaluza de Enfermedades InfecciosasConsejeria de Salud. Junta de Andalucia. SpainCompletedHIV Infection | HIV-1 InfectionSpain
-
ANRS, Emerging Infectious DiseasesUniversity College London Hospitals; Hospital Clinic of Barcelona; Imperial College... and other collaboratorsCompletedHIV-1-infectionFrance, United Kingdom, Switzerland
-
Helios SaludViiV HealthcareUnknownHiv | HIV-1-infectionArgentina
-
Frontier Biotechnologies Inc.RecruitingHIV-1-infectionUnited States
-
University of ZurichActive, not recruitingHIV-1-infectionSwitzerland
-
MacroGenicsNational Institute of Allergy and Infectious Diseases (NIAID)CompletedHIV-1-infectionUnited States
-
Fundación FLS de Lucha Contra el Sida, las Enfermedades...Aelix TherapeuticsCompleted
-
University of North Carolina, Chapel HillNational Institute of Allergy and Infectious Diseases (NIAID)CompletedHIV-1 InfectionUnited States
-
Taipei Veterans General Hospital, TaiwanCompleted
Clinical Trials on Antiretroviral treatment interruption
-
Rockefeller UniversityNational Institute of Allergy and Infectious Diseases (NIAID); Montefiore Medical... and other collaboratorsCompleted
-
National Institute of Allergy and Infectious Diseases...WithdrawnHIV InfectionsUnited States, Puerto Rico
-
National Institute of Allergy and Infectious Diseases...Withdrawn
-
Hospital Clinic of BarcelonaCompletedHIV-Associated Lipodystrophy SyndromeSpain
-
Tel-Aviv Sourasky Medical CenterUnknownHIV Infections
-
University Hospital, GenevaCompletedHIV Infection | AIDSSwitzerland
-
University of North Carolina, Chapel HillNational Institute on Drug Abuse (NIDA); National Institute on Alcohol Abuse... and other collaboratorsWithdrawn
-
A.O. Ospedale Papa Giovanni XXIIICompleted
-
The Wistar InstituteCompleted
-
American Gene Technologies International Inc.Enrolling by invitation